GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 15, 2024 17:00 ET
|
GT Biopharma, Inc.
IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemia expected in Q2 2024Phase 1 trial initiation with GTB-3650 expected in 2H 2024Anticipate IND submission for...